Ascelia Pharma

Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study

2 May 2023 -- Malmö, Sweden -- Ascelia Pharma, a biotech focused on improving the life of people living with rare cancer conditions, today announced that liver imaging drug candidate, Orviglance, significantly improved visualisation of focal liver lesions, successfully meeting the primary endpoint in the pivotal phase 3 study SPARKLE. Investors and analysts are invited...

Ascelia Pharma presented Orviglance Hepatic Impairment Data and hosted a Q&A with liver imaging experts at the 2023 ESGAR Annual Meeting

16 June 2023 -- Malmˆ, Sweden -- Ascelia Pharma AB, a biotech focused on improving the life of people living with rare cancer conditions, today announced that data from the companyís Hepatic Impairment Study were presented at the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Annual Meeting in Valencia, Spain, June 13-16, 2023. The...

Ascelia Pharma meets major milestone with patient enrollment completion of Phase 3 Study for Orviglance, novel MRI contrast agent for patients with kidney impairment

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the successful completion of patient enrollment in the companyís pivotal phase 3 clinical study, SPARKLE, with the lead candidate drug Orviglance.
Hyllie Stationstorg 31 215 32 Malmö

+46 735 17 91 18